DROPERIDOL LACTATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H22FN3O2.C3H6O3
Molecular Weight	469.5053
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4

InChI

InChIKey=CUYSTLHETVVORS-UHFFFAOYSA-N

InChI=1S/C22H22FN3O2.C3H6O3/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28;1-2(4)3(5)6/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28);2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula	C22H22FN3O2
Molecular Weight	379.4274
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/droperidol.html

Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00450	Antagonist 2849
Alpha-1a adrenergic receptor 67 Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00450	Antagonist 2849
HERG 99 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12190308	Inhibitor 8504	32.2 nM [IC50]
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2879412	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nausea and vomiting associated with surgical and diagnostic procedures 2 Sources: https://www.drugs.com/pro/droperidol.html	Secondary		Approved 8583	INAPSINE Approved Use Droperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. Launch Date 1970

C_max

Value	Dose	Co-administered	Analyte	Population
26.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
40 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985	unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985	Disc. AE: QT interval prolonged... AEs leading to discontinuation/dose reduction: QT interval prolonged Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985
8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	Other AEs: Asthenia, Chills... Other AEs: Asthenia (24.6%) Chills (3.3%) Anorexia (3.3%) Akathisia (16.4%) Anxiety (27.9%) Confusion (3.3%) Dizziness (9.8%) Dry mouth (9.8%) Nervousness (4.9%) Paresthesia (3.3%) Somnolence (24.6%) Tremor (1.6%) Pharyngitis (4.9%) Rhinitis (4.9%) Sweaty (8.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
2.5 mg multiple, intravenous Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x	Disc. AE: Torsades de pointes... AEs leading to discontinuation/dose reduction: Torsades de pointes Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP1 116	CYP3A5 446

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
MRP1 232	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/dmd/early/2018/09/19/dmd.118.081612.full.pdf Page: 19.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2803%2990413-9	major
CYP3A5 446	substrate 4014 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2803%2990413-9	major

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/18349188/

Sourcing

Vendor/Aggregator	ID	URL
PubChem	9956314	https://pubchem.ncbi.nlm.nih.gov/compound/9956314
SureChEMBL	SCHEMBL8356614	https://www.surechembl.org/chemical/SCHEMBL8356614
Wikidata	Q27236492

PubMed

Title	Date	PubMed
[Postoperative nausea and vomiting--still a problem?].	2001	11455867
Ondansetron: a review of its use as an antiemetic in children.	2001	11437189
Droperidol for acute psychosis.	2001	11406047
A small dose of droperidol decreases postoperative nausea and vomiting in adults but cannot improve an already excellent patient satisfaction.	2001 Apr	11300391
Patient-controlled epidural analgesia versus continuous epidural analgesia after total knee arthroplasty.	2001 Apr	11300386
[The influence of age on hemodynamics and the dose requirements of propofol and buprenorphine in total intravenous anesthesia combined with continuous epidural anesthesia].	2001 Aug	11554014
[Intraoperative memory. A study of its incidence in general anesthesia in 326 patients].	2001 Aug	11530746
[Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?].	2001 Aug 5	11556262
Preparation, premedication, and surveillance.	2001 Feb	11272212
[Prevention of postoperative nausea and vomiting in gynecologic surgery with 3 fixed doses of metoclopramide, droperidol or placebo].	2001 Feb	11257953
Evaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic review.	2001 Feb	11218733
Suppression of potassium conductance by droperidol has influence on excitability of spinal sensory neurons.	2001 Feb	11176093
Prevention of postoperative nausea and vomiting with antiemetics in patients undergoing middle ear surgery: comparison of a small dose of propofol with droperidol or metoclopramide.	2001 Jan	11177010
Randomised double-blind comparison of ondansetron and droperidol to prevent postoperative nausea and vomiting associated with patient-controlled analgesia.	2001 Jan	11167438
Droperidol: an effective adjuvant for difficult cases of conscious sedation?	2001 Jul	11493944
Combination of droperidol and ondansetron reduces PONV after pediatric strabismus surgery more than single drug therapy.	2001 Jul	11421836
Plasma glucocorticoid concentrations after fentanyl-droperidol, ketamine-xylazine and ketamine-diazepam anaesthesia in New Zealand white rabbits.	2001 Jun 23	11465268
Effects on the bispectral index during elective caesarean section: a comparison of propofol and isoflurane.	2001 Mar	11407290
Neuroleptic malignant syndrome induced by droperidol.	2001 Mar	11406684
Pediatric renal transplantation: anesthesia and perioperative complications.	2001 Mar	11315282
Small doses of propofol, droperidol, and metoclopramide for the prevention of postoperative nausea and vomiting after thyroidectomy.	2001 Mar	11240988
Comparison of granisetron, droperidol, and metoclopramide for prevention of postoperative vomiting in children with a history of motion sickness undergoing tonsillectomy.	2001 Mar	11226996
Dexamethasone for preventing nausea and vomiting associated with epidural morphine: a dose-ranging study.	2001 Mar	11226112
[Droperidol and dimenhydrinate alone or in combination for prevention of postoperative nausea and vomiting].	2001 May	11413698
In vitro neuromuscular effects of droperidol in rats.	2001 May	11400565
[Therapy of angina pectoris: morphine or thalamonal?].	2001 May 11	11402918
Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.	2001 Nov	11691681
IM droperidol as premedication attenuates intraoperative hypothermia.	2001 Oct	11606340
[Postoperative nausea--still a problem].	2001 Oct 3	11685757
Droperidol vs. prochlorperazine for benign headaches in the emergency department.	2001 Sep	11535479
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.	2002	12109926
The black box warning.	2002 Fall	12380043
[Continuous epidural administration of droperidol to prevent postoperative nausea and vomiting].	2002 Feb	11889776
Premedication, preparation, and surveillance.	2002 Jan	11778125
Droperidol "box warning" warrants scrutiny.	2002 Jul	12131146
FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified?	2002 Jul	12131145
Dolasetron decreases postoperative nausea and vomiting after breast surgery.	2002 Jul-Aug	12100113
Gateways to Clinical Trials. June 2002.	2002 Jun	12168506
Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial.	2002 Jun	12045085
Rapid tranquillisation: time for a reappraisal of options for parenteral therapy.	2002 Jun	12042225
Arrhythmias from droperidol?	2002 Jun 10	12058151
Derivative spectrophotometric determination of droperidol in presence of parabens.	2002 Jun 20	12062683
Continuous epidural, not intravenous, droperidol inhibits pruritus, nausea, and vomiting during epidural morphine analgesia.	2002 Mar	11943525
Inapsine. Weighing the risk of fatal arrhythmias.	2002 Mar	11902037
Using imprecise probabilities to address the questions of inference and decision in randomized clinical trials.	2002 May	12060416
Psychotropic drugs and the ECG: focus on the QTc interval.	2002 May	11996627
Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery.	2002 May	11981150
LC determination and degradation study of droperidol.	2002 May 15	12008124
Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics.	2002 May-Jun	12113564
Effects of anesthesia on efferent-mediated adaptation of the DPOAE.	2002 Sep	12382109

Patents

Sample Use Guides

In Vivo Use Guide

Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely. Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.

Route of Administration: Intravenous

In Vitro Use Guide

Droperidol (10(-7) M) caused vasodilator effect (approximately 20% of vasorelaxation compared with maximal vasorelaxation induced by papaverine [3 x 10(-4) M] in rat vascular smooth muscle cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:25:41 GMT 2025` Edited by `admin` on `Mon Mar 31 22:25:41 GMT 2025`
Record UNII	09NO5N37E0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DROPERIDOL DL-LACTATE

Preferred Name

English

DROPERIDOL LACTATE

Common Name

English

2-HYDROXYPROPANOIC ACID - 1-(1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE (1:1)

Systematic Name

English

1-(1-(3-(P-FLUOROBENZOYL)PROPYL)-1,2,3,6-TETRAHYDRO-4-PYRIDYL)-2-BENZIMIDAZOLINONE 2-HYDROXYPROPANOIC ACID

Systematic Name

English

Droperidol lactate [WHO-DD]

Common Name

English

3-(1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-3,6-DIHYDRO-2H-PYRIDIN-4-YL)-1H-BENZIMIDAZOL-2-ONE 2-HYDROXYPROPANOIC ACID

Systematic Name

English

Code System Code Type Description

EVMPD

SUB01839MIG

Created by admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025

PRIMARY

PUBCHEM

9956314

Created by admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025

PRIMARY

FDA UNII

09NO5N37E0

Created by admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025

PRIMARY

SMS_ID

100000087719

Created by admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025

PRIMARY

Related Record Type Details


					O9U0F09D5X

DROPERIDOL

PARENT -> SALT/SOLVATE

Related Record Type Details


					O9U0F09D5X

DROPERIDOL

ACTIVE MOIETY

AE	Significance	Dose	Population
QT interval prolonged	Disc. AE	0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985	unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985
Tremor	1.6%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Akathisia	16.4%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Asthenia	24.6%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Somnolence	24.6%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Anxiety	27.9%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Anorexia	3.3%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Chills	3.3%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Confusion	3.3%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Paresthesia	3.3%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Nervousness	4.9%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Pharyngitis	4.9%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Rhinitis	4.9%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Sweaty	8.2%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Dizziness	9.8%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Dry mouth	9.8%	8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
Torsades de pointes	Disc. AE	2.5 mg multiple, intravenous Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00450Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/droperidol.html

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/droperidol.html

C_max

T_1/2

Drug as perpetrator